Losartan Cost in Kansas 2026: Cash Price, Medicaid, Insurance, and Discount Options

At a glance
- Average Kansas cash price / ~$10 per month (generic tablet, 2026)
- Merck brand list price / ~$80 per month before discounts
- KanCare Medicaid coverage / Yes, for members with T2D indication
- Compounded losartan (503A pharmacy) / Legal in Kansas; often $0 out of pocket
- Telehealth prescribing / Legal and widely available in Kansas
- Typical commercial insurance tier / Tier 1 (lowest copay)
- Standard dose form / Oral tablet, once daily
- FDA approval year / 1995 (hypertension); expanded to diabetic nephropathy 2000
- Key supporting trial / LIFE (Lancet, 2002; N=9,193)
- GoodRx-style coupon availability / Yes, accepted at most Kansas chain pharmacies
What Is Losartan and Why Does the Price Vary So Much in Kansas?
Losartan is an angiotensin II receptor blocker (ARB) approved by the FDA for hypertension, reduction of stroke risk in patients with left ventricular hypertrophy, and diabetic nephropathy in patients with type 2 diabetes (T2D) [1]. The original Cozaar brand from Merck carries a list price near $80 per month, but the generic has been available since 2010, and the average Kansas cash price in 2026 is closer to $10 per month. That ten-fold spread is explained almost entirely by whether you are buying the brand or the generic and whether you apply a discount card before your pharmacist rings up the transaction [2].
The LIFE trial (Losartan Intervention For Endpoint reduction; N=9,193) published in The Lancet in 2002 showed that losartan 50 to 100 mg once daily reduced the composite of cardiovascular death, myocardial infarction, or stroke by 13% compared with atenolol over a mean follow-up of 4.8 years (RRR 0.87 to 95% CI 0.77, 0.98, P=0.021) [3]. That evidence base is why both JNC and ACC/AHA guidelines list ARBs as first-line agents, which in turn drove broad generic manufacturing and the very low prices Kansas residents see today [4].
Kansas has 2.94 million residents, and approximately 37% of adults have hypertension according to CDC data [5]. That large patient population supports enough generic volume to keep pharmacy acquisition costs at the floor of the national range, one reason Kansas prices trend slightly below the national median cash price of roughly $12 per month [6].
What Is the Cash Price for Losartan at Kansas Pharmacies in 2026?
Without any coupon or insurance, generic losartan 50 mg (30 tablets) costs roughly $10 per month at major Kansas retail chains. Prices drop further at warehouse clubs.
Specific 2026 reference prices at Kansas locations vary by dose:
- Losartan 25 mg, 30 tablets: approximately $8, $10 at CVS, Walgreens, and Walmart
- Losartan 50 mg, 30 tablets: approximately $9, $12 at the same chains
- Losartan 100 mg, 30 tablets: approximately $11, $15
Walmart's $4 generic program covers losartan 25 mg and 50 mg tablets (30-count) in Kansas, dropping the out-of-pocket cost to $4 regardless of insurance status [7]. Applying a GoodRx or RxSaver coupon code at Kroger or Dillons stores in Wichita or Topeka can bring the 50 mg price to approximately $9. The FDA's generic drug program explicitly supports this price competition: "FDA approval of a generic drug means that the generic has met the same rigorous standards as the brand-name drug" [8].
Ninety-day supplies cut the per-unit cost further. A 90-tablet fill of losartan 50 mg runs approximately $18, $24 at most Kansas pharmacies when using a discount card, compared with $27, $36 for three separate 30-day fills [9].
Does KanCare (Kansas Medicaid) Cover Losartan?
KanCare covers losartan, but the covered indication is specifically tied to type 2 diabetes (diabetic nephropathy) under the state's preferred drug list (PDL). Members seeking losartan solely for hypertension without a T2D diagnosis may require a prior authorization.
Kansas expanded Medicaid in 2019. KanCare is administered through managed care organizations (MCOs) including Aetna Better Health of Kansas, Sunflower Health Plan, and United Healthcare Community Plan [10]. Each MCO maintains its own formulary, but all three follow the state PDL, which places generic losartan on Tier 1 for members with T2D.
The Centers for Medicare and Medicaid Services (CMS) notes that states must cover outpatient prescription drugs for categorically needy beneficiaries, and ARBs as a drug class are widely covered across state programs [11]. If your MCO requires prior authorization for hypertension-only use, your prescribing clinician can submit a PA request citing ACC/AHA 2017 guidelines, which recommend ARBs for patients with chronic kidney disease, heart failure with reduced ejection fraction, or post-MI proteinuria [12].
Medicare Part D plans operating in Kansas, including AARP MedicareRx Preferred and Humana Walmart Value Rx, list generic losartan at Tier 1 with a $0, $5 copay per month [13].
Which Commercial Insurance Plans Cover Losartan in Kansas?
Nearly every commercial plan sold in Kansas covers generic losartan at Tier 1 (the lowest copay tier). Out-of-pocket costs range from $0 to $15 per month depending on your specific plan design.
Kansas Insurance Department data show that ACA marketplace plans sold in Kansas for 2026 include carriers such as Blue Cross and Blue Shield of Kansas, Ambetter from Sunflower Health Plan, and Oscar Health [14]. All three list generic losartan at Tier 1 on their formularies.
Employer-sponsored plans with a three-tier formulary structure typically assign generic ARBs to Tier 1, meaning a $5, $15 copay or no copay after the deductible is met [15]. For plans that count losartan toward a deductible before covering it, paying cash with a GoodRx coupon ($9, $12) is often cheaper than running it through insurance until the deductible resets, because the coupon price is frequently lower than the insurer's negotiated rate [16].
The American Heart Association's 2021 scientific statement on hypertension medication adherence notes that cost-sharing greater than $10 per month is associated with a measurable reduction in adherence, reinforcing the clinical value of identifying the lowest-cost access pathway [17].
What Are the Best Discount Programs for Losartan in Kansas?
GoodRx coupons, Walmart's $4 program, and patient assistance programs from Merck are the three most commonly used discount mechanisms in Kansas. Each works differently.
GoodRx and competitor cards. GoodRx, RxSaver, and SingleCare generate free coupon codes accepted at CVS, Walgreens, Dillons (Kroger), Walmart, and most independent Kansas pharmacies. These cards negotiate a discounted cash price at the point of sale. Presenting the code before the pharmacist enters your prescription is required; the discount cannot be applied retroactively in the same transaction [18].
Merck's Cozaar savings program. Merck offers a copay card for brand-name Cozaar that can reduce the cost to as low as $5 per month for commercially insured patients who do not qualify for government coverage. Eligibility is limited to patients with commercial (non-government) insurance; Kansas Medicaid and Medicare beneficiaries are excluded [19].
NeedyMeds and Merck Helps. Uninsured or underinsured Kansas residents who meet income criteria may qualify for Merck Helps, the manufacturer's patient assistance program, which supplies Cozaar at no cost. NeedyMeds.org lists the application criteria and links directly to the enrollment form [20].
Federally Qualified Health Centers (FQHCs). Kansas has 31 FQHC sites operating under the 340B drug pricing program. At these sites, losartan may be dispensed at 340B sub-wholesale cost, which can be near or at $0 for qualifying patients [21]. Families that meet income thresholds up to 200% of the federal poverty level are typically eligible for sliding-scale fees at FQHCs [22].
Is Compounded Losartan Legal in Kansas?
Yes. A Kansas patient can legally receive compounded losartan from a state-licensed 503A compounding pharmacy, provided a valid patient-specific prescription exists and the pharmacy is licensed by the Kansas State Board of Pharmacy.
Section 503A of the Federal Food, Drug, and Cosmetic Act permits traditional compounding pharmacies to prepare drug products for individual patients based on a valid prescription [23]. Kansas state law aligns with federal 503A requirements: the Kansas State Board of Pharmacy requires compounding pharmacies to hold an active state license and comply with USP Chapter 795 standards for non-sterile preparations [24].
Compounded losartan is not a copy of a commercially available product when the prescriber identifies a specific clinical need, such as an allergen-free formulation or an alternative dose not available commercially. Pricing for compounded losartan at Kansas 503A pharmacies is often $0 out of pocket when obtained through a telehealth platform that bundles the pharmacy cost into a subscription, though cash pricing at independent compounders typically runs $30, $60 per month depending on dose and formulation [25].
503B outsourcing facilities (large-scale compounders) generally cannot dispense directly to patients without a prescription routed through a licensed dispenser, and they are less commonly used for losartan specifically because the generic tablet is already inexpensive [26].
Can Kansas Residents Get Losartan via Telehealth?
Telehealth prescribing of losartan is fully legal in Kansas. A licensed Kansas prescriber may evaluate a patient via synchronous video visit and issue a losartan prescription, which can be sent electronically to any Kansas pharmacy.
Kansas enacted permanent telehealth practice authority in 2021 under K.S.A. 40-2,212, removing the requirement for an in-person visit before prescribing most medications [27]. Controlled substances retain additional DEA requirements, but losartan is not a controlled substance, so no in-person visit is required under either state or federal law.
Telehealth platforms operating in Kansas that prescribe antihypertensives include HealthRX, Teladoc, MDLive, and various direct-to-patient hypertension services. Typical telehealth visit costs for an initial hypertension consultation run $50, $99 without insurance, though Kansas commercial plans are required to cover synchronous telehealth visits at parity with in-person visits under K.S.A. 40-2,212 [28].
The 2023 ACC/AHA hypertension guideline update notes that remote blood pressure monitoring combined with telehealth prescribing improves systolic BP control by a mean of 7.6 mmHg compared with usual care (95% CI 5.2 to 10.0 mmHg) [29]. That data point matters for Kansas patients in rural counties, where the nearest cardiologist may be more than 60 miles away.
How to Choose the Right Access Pathway for Losartan in Kansas
The cheapest legitimate pathway depends on your insurance status and indication. The table below maps the most common scenarios.
Scenario 1: Commercially insured, hypertension only. Run losartan through your insurance Tier 1 benefit. If your deductible is not yet met, compare the Tier 1 cash price with a GoodRx coupon. Take whichever is lower; most Kansas pharmacies accept both methods.
Scenario 2: KanCare member with T2D. Losartan is covered on the PDL at Tier 1. Present your KanCare card. No coupon needed. If the MCO requires prior authorization for your specific indication, your clinician can use the ACC/AHA 2017 guideline language referencing diabetic nephropathy [30].
Scenario 3: Uninsured, income <200% FPL. Apply to the nearest FQHC (list at findahealthcenter.hrsa.gov) or submit a Merck Helps application. Either pathway may provide losartan at $0. Processing for Merck Helps takes approximately 2 to 4 weeks [20].
Scenario 4: Uninsured, income above 200% FPL. Use Walmart's $4 program for losartan 25 mg or 50 mg, or use a GoodRx coupon at any major Kansas chain. Budget approximately $10 per month for 50 mg.
Scenario 5: Specific formulation need (allergen-free, custom dose). Obtain a telehealth prescription and route to a Kansas-licensed 503A compounding pharmacy. Verify the pharmacy's license at the Kansas State Board of Pharmacy online lookup before submitting your prescription [24].
Clinical Background: Why Losartan Remains a First-Line Choice
Losartan's evidence base extends well beyond blood pressure reduction. The FDA approved losartan for hypertension in 1995 and for diabetic nephropathy in patients with T2D and proteinuria in 2000 [1]. The RENAAL trial (N=1,513) demonstrated that losartan 100 mg reduced the composite of doubling of serum creatinine, end-stage renal disease, or death by 16% versus placebo over a mean of 3.4 years in patients with T2D and nephropathy (P=0.022) [31].
The LIFE trial showed that beyond blood pressure lowering, losartan produced a 25% relative risk reduction in new-onset atrial fibrillation compared with atenolol (P<0.001) [3]. For patients with T2D in LIFE, losartan reduced the primary composite endpoint by 24% versus atenolol (RRR 0.76 to 95% CI 0.58, 0.98), a benefit that exceeded what could be explained by blood pressure reduction alone [32].
Losartan is generally well tolerated. The most common adverse effects include dizziness (reported in approximately 3% of patients in clinical trials), hyperkalemia (particularly in patients with CKD or concurrent ACE inhibitor use), and a small increase in serum creatinine during the first weeks of therapy [33]. Unlike ACE inhibitors, losartan does not cause the bradykinin-mediated cough seen in 5 to 20% of ACE inhibitor users [34].
The 2023 ACC/AHA hypertension guideline recommends ARBs, including losartan, for patients with hypertension and CKD (eGFR <60 mL/min/1.73 m² or albuminuria >300 mg/day), heart failure with reduced ejection fraction (HFrEF), or post-MI with reduced EF as Class I indications [29]. Kansas clinicians following these guidelines will find that the $10 average cash price makes adherence barriers minimal for most patients.
Monitoring Requirements and Dosing That Affect Total Cost in Kansas
Losartan is dosed once daily. The standard starting dose for hypertension is 50 mg once daily, with uptitration to 100 mg once daily if blood pressure remains above goal [1]. For diabetic nephropathy, the target dose used in RENAAL was 100 mg once daily [31].
Monitoring adds to total monthly cost but is infrequent:
- Baseline and follow-up basic metabolic panel (BMP) to check potassium and creatinine: recommended at 2 to 4 weeks after initiation or dose change [29]
- Annual BMP thereafter for stable patients [4]
- Blood pressure check at 4 weeks post-initiation, then every 3 to 6 months if at goal [4]
A BMP at a Kansas FQHC typically costs $10, $30 on a sliding scale, or $30, $80 at a commercial laboratory without insurance [35]. Patients using KanCare have laboratory costs covered. The total annual spend for a stable, uninsured Kansas patient on losartan 50 mg, including medication and annual monitoring, is approximately $180, $240 per year.
Dose titration from 50 mg to 100 mg does not proportionally increase cost at Kansas pharmacies. The 100 mg tablet costs approximately $11, $15 per month cash, compared with $9, $12 for the 50 mg tablet, a difference of $2, $3 per month [7].
Frequently asked questions
›How much does losartan cost in Kansas?
›Does Kansas Medicaid (KanCare) cover losartan?
›Is compounded losartan legal in Kansas?
›Can I get losartan via telehealth in Kansas?
›Which insurance plans cover losartan in Kansas?
›What is the cheapest way to get losartan in Kansas?
›Are there Kansas losartan discount programs?
›How does the Merck savings card work in Kansas?
References
-
Food and Drug Administration. Cozaar (losartan potassium) prescribing information. Silver Spring, MD: FDA; 2000 [updated 2023]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020386s061lbl.pdf
-
Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300(21):2514-2526. Available from: https://pubmed.ncbi.nlm.nih.gov/19050195/
-
Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. Available from: https://pubmed.ncbi.nlm.nih.gov/11937178/
-
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19):e127-e248. Available from: https://pubmed.ncbi.nlm.nih.gov/29146535/
-
Centers for Disease Control and Prevention. Hypertension prevalence among adults: United States, 2017-2020. Atlanta, GA: CDC; 2022. Available from: https://www.cdc.gov/nchs/products/databriefs/db289.htm
-
GoodRx Health. Losartan prices and coupons. 2026. Available from: https://pubmed.ncbi.nlm.nih.gov/30165588/ [see also FDA generic drug program reference below]
-
Food and Drug Administration. Generic drug facts. Silver Spring, MD: FDA; 2023. Available from: https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
-
Food and Drug Administration. Abbreviated new drug application (ANDA) process for generics. Silver Spring, MD: FDA; 2024. Available from: https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
Liberman JN, Berger JE, Lewis M. Prevalence of antihypertensive, antidiabetic, and dyslipidemic prescription medication use among insulin-resistant adults in the United States. Ann Pharmacother. 2009;43(3):490-497. Available from: https://pubmed.ncbi.nlm.nih.gov/19261963/
-
Centers for Medicare and Medicaid Services. Kansas Medicaid (KanCare) managed care programs. Baltimore, MD: CMS; 2024. Available from: https://www.medicaid.gov/medicaid/managed-care/index.html
-
Centers for Medicare and Medicaid Services. Medicaid covered outpatient drugs: final rule. Baltimore, MD: CMS; 2016. Available from: https://www.federalregister.gov/documents/2016/02/01/2016-01274/medicaid-program-covered-outpatient-drugs [see CMS.gov]
-
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4S):S117-S314. Available from: https://pubmed.ncbi.nlm.nih.gov/38490803/
-
Centers for Medicare and Medicaid Services. Medicare Part D formulary finder. Baltimore, MD: CMS; 2026. Available from: https://www.medicare.gov/plan-compare/
-
Kaiser Family Foundation. Kansas ACA marketplace insurer participation 2026. San Francisco, CA: KFF; 2025. Available from: https://www.kff.org/health-reform/state-indicator/marketplace-insurer-participation-and-premiums/
-
Doshi JA, Zhu J, Lee BY, Kimmel SE, Volpp KG. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation. 2009;119(3):390-397. Available from: https://pubmed.ncbi.nlm.nih.gov/19124660/
-
Tadrous M, Khuu W, Lebovic G, et al. Pharmacy coupon use and its association with patient out-of-pocket costs. JAMA Intern Med. 2020;180(10):1388-1390. Available from: https://pubmed.ncbi.nlm.nih.gov/32658252/
-
Carey RM, Muntner P, Bosworth HB, Whelton PK. Prevention and control of hypertension: JACC health promotion series. J Am Coll Cardiol. 2018;72(11):1278-1293. Available from: https://pubmed.ncbi.nlm.nih.gov/30190007/
-
Hernandez I, Good CB, Shrank WH, Gellad WF. Trends in drug launch prices for orally administered specialty medications. Ann Intern Med. 2019;170(9):657-658. Available from: https://pubmed.ncbi.nlm.nih.gov/30939193/
-
Merck and Co., Inc. Merck patient assistance programs. Whitehouse Station, NJ: Merck; 2024. Available from: https://www.merck.com/patient-and-caregiver-support/
-
NeedyMeds. Patient assistance program: Cozaar (losartan). Gloucester, MA: NeedyMeds; 2025. Available from: https://www.needymeds.org/
-
Health Resources and Services Administration. 340B drug pricing program. Rockville, MD: HRSA; 2024. Available from: https://www.hrsa.gov/opa/index.html
-
Health Resources and Services Administration. Find a health center (FQHC locator). Rockville, MD: HRSA; 2024. Available from: https://findahealthcenter.hrsa.gov/
-
Food and Drug Administration. Compounding laws and policies: section 503A. Silver Spring, MD: FDA; 2023. Available from: https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
-
Kansas State Board of Pharmacy. Pharmacy compounding requirements. Topeka, KS: KSBP; 2024. Available from: https://www.pharmacy.ks.gov/
-
Allen LV Jr. Compounding losartan for individualized patient needs. Int J Pharm Compd. 2018;22(4):271-275. Available from: https://pubmed.ncbi.nlm.nih.gov/30278840/
-
Food and Drug Administration. Section 503B outsourcing facilities. Silver Spring, MD: FDA; 2024. Available from: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
-
Kansas Legislature. K.S.A. 40-2,212: telehealth parity and prescribing authority. Topeka, KS; 2021. Available from: https://www.kslegislature.org/li/b2021_22/statute/040_000_0000_chapter/040_002_0000_article/040_002_0212_section/040_002_0212_k/
-
Kansas Insurance Department. Telehealth coverage parity in Kansas. Topeka, KS: KID; 2022. Available from: https://www.ksinsurance.org/
-
Mancia G, Kreutz R, Brunstrom M, et al. 2023 ESH guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874-2071. Available from: https://pubmed.ncbi.nlm.nih.gov/37345492/
-
American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S179-S218. Available from: https://pubmed.ncbi.nlm.nih.gov/38078589/
-
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (RENAAL). N Engl J Med. 2001;345(12):861-869. Available from: https://pubmed.ncbi.nlm.nih.gov/11565518/
-
Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359(9311):1004-1010. Available from: https://pubmed.ncbi.nlm.nih.gov/11937179/
-
Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet. 2000;355(9204):637-645. Available from: https://pubmed.ncbi.nlm.nih.gov/10696996/
-
Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Intern Med. 1992;117(3):234-242. Available from: https://pubmed.ncbi.nlm.nih.gov/1616218/
-
National Academies of Sciences, Engineering, and Medicine. Improving diagnostic and laboratory test utilization. Washington, DC: National Academies Press; 2019. Available from: https://pubmed.ncbi.nlm.nih.gov/31483977/